PTC Therapeutics has been granted a patent for compounds, forms, and pharmaceutical compositions for treating Huntington’s disease. The patent specifically covers substituted bicyclic heterocyclic and heteroaryl compounds of Formula (I). GlobalData’s report on PTC Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights PTC Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on PTC Therapeutics, Human telomerase RT biomarker was a key innovation area identified from patents. PTC Therapeutics's grant share as of January 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11858941B2) discloses a compound of Formula (Ibbl) and its various forms, with R1 being a heterocyclyl group selected from a range of options such as azetidinyl, tetrahydrofuranyl, and piperidinyl. The patent also covers a method for treating or ameliorating Huntington's Disease (HD) by administering an effective amount of the compound to a subject in need, with the dosage ranging from about 0.001 mg/kg/day to 500 mg/kg/day.

Furthermore, the patent includes claims for pharmaceutical compositions containing the disclosed compound or its forms, along with pharmaceutically acceptable excipients. Additionally, methods for treating HD using specific compounds or forms thereof, as well as compound salts, are detailed in the patent. The effective dosage for these treatments falls within the range of 0.001 mg/kg/day to 500 mg/kg/day, providing a comprehensive framework for potential therapeutic interventions for HD.

To know more about GlobalData’s detailed insights on PTC Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies